Keyphrases
Von Willebrand Disease
100%
Factor VIII Concentrate
100%
Von Willebrand Factor
100%
Factor VIII (FVIII)
55%
Fetal Sheep
50%
Pre-surgical
50%
Lamb
50%
Pharmacokinetic Analysis
50%
Human Cells
50%
Elective Surgery
50%
Limited Value
50%
Diamond-Blackfan Anemia
50%
Immune Tolerance Induction
50%
Plasma-derived FVIII
50%
Hematopoietic Cells
50%
Long-term Engraftment
50%
Hypofibrinogenemia
41%
Engraftment
33%
Chimerism
33%
Plasma-derived Factor VIII
27%
Pharmacokinetic Evaluation
27%
Adverse Events
26%
B-CLL
25%
Fibrinogen
25%
Joint Bleeding
21%
After Surgery
20%
Hemostatic Efficacy
18%
Major Surgery
18%
Bone Marrow Cells
16%
Allergic Reaction
16%
Hematopoietic Stem Cells
16%
Surgery Risk
16%
Non-obstetric
16%
Bone Marrow
16%
Thrombosis
16%
Transplantation
16%
Sheep
16%
Increased Mortality
16%
Surgery Alone
16%
Surgical Procedures
14%
Change from Baseline
14%
Erythroid Response
14%
Dual-color Fluorescence in Situ Hybridization
12%
Hyperdiploid
12%
Hypodiploidy
12%
Before Surgery
10%
Optimal Dosing
10%
In(III)
10%
Inherited Bleeding Disorders
10%
Clinical Practice Guidelines
10%
Medicine and Dentistry
Von Willebrand Factor
100%
Bleeding
61%
Anemia
50%
Von Willebrand Disease
50%
Diamond-Blackfan Anemia
50%
Haemophilia A
50%
Leucine
50%
Substitution Therapy
50%
Immunological Tolerance
50%
Fibrinogen
50%
Blood Clotting Factor 8
35%
Blood Clotting Factor 8 Concentrate
27%
Ciclonicate
21%
Adverse Event
14%
Hemarthrosis
14%
Ribosome Protein
14%
Afibrinogenemia
11%
Obstetrics
11%
Allergic Response
7%
Thrombosis
7%
Hematopoietic Stem Cell Transplantation
7%
Congenital Malformation
7%
Cancer Susceptibility
7%
Multivariate Analysis
7%
Haploinsufficiency
7%
Infusion
7%
Cerebral Hemorrhage
7%
Clinical Trial
7%
Corticosteroid Therapy
7%
Body Mass Index
7%
Bone Marrow Failure
7%
Bleeding Disorder
7%
Growth Rate
7%
Marrow Failure Syndrome
7%
Diseases
7%
Joint Function
7%
Short Stature
7%
Pediatrics
5%
Pharmacology, Toxicology and Pharmaceutical Science
Von Willebrand Factor
100%
Von Willebrand Disease
100%
Blood Clotting Factor 8 Concentrate
100%
Fibrinogen
50%
Replacement Therapy
50%
Bleeding
24%
Adverse Event
13%
Ristocetin
12%
Hemostatic Agent
10%
Allergic Reaction
7%
Thrombosis
7%
Blood Stasis
6%
Bleeding Disorder
6%
